{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-062918","form_type":"8-K","ticker":"KZR","cik":"0001645666","company_name":"Kezar Life Sciences, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.925802+00:00","generated_at":"2026-06-08T05:15:01.769233+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kezar Q3 net loss $23.1M; appoints new CEO, restructures to extend cash runway into 2026","bullets":["Net loss of $23.1M ($0.32/share) vs $17.8M loss in Q3 2022; revenue of $7.0M from Everest upfront.","Cash, equivalents, marketable securities $218.2M at Sep 30, down from $276.6M at Dec 31, 2022.","Co-founder Christopher Kirk appointed CEO Nov 7, replacing John Fowler who remains on board.","Strategic restructuring pauses drug discovery, extends cash runway into late 2026; focuses on zetomipzomib and KZR-261.","Collaboration with Everest Medicines for zetomipzomib in Greater China, South Korea, SE Asia; Everest joins PALIZADE trial."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-062918","json":"https://secwatch.observer/filing/0000950170-23-062918.json","markdown":"https://secwatch.observer/filing/0000950170-23-062918.md","text":"https://secwatch.observer/filing/0000950170-23-062918.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645666/000095017023062918/0000950170-23-062918-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645666/000095017023062918/kzr-20231113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:15:01.769233+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"57621cb48ec9dd651689fd1b32ada0a620d3c9fd","claim":"Kezar Life Sciences, Inc. reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"On November 13, 2023, Kezar Life Sciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645666/000095017023062918/0000950170-23-062918-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}